Identifying and exploiting synthetic lethal dependencies of cancer cells with aberrant histone ubiquitination will enable the development of therapeutic strategies that bypass the potential pleiotropic off-target effects associated with direct targeting of an aberrantly expressed histone E3 ubiquitin ligase or DUB. Here, ZUP1 is linked to cancer.